Back to top

Sobi’s Tryngolza cuts pancreatitis risk 85% in severe hypertriglyceridemia trial analysis

An announcement from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) is now available. Sobi reported new pooled Phase 3 data showing that its RNA-target...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Swedish Orphan Biovitrum (BIOVF)